DK0506884T3 - Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler - Google Patents
Fremgangsmåde til afgivelse af molekyler til eukaryotiske cellerInfo
- Publication number
- DK0506884T3 DK0506884T3 DK91903111.2T DK91903111T DK0506884T3 DK 0506884 T3 DK0506884 T3 DK 0506884T3 DK 91903111 T DK91903111 T DK 91903111T DK 0506884 T3 DK0506884 T3 DK 0506884T3
- Authority
- DK
- Denmark
- Prior art keywords
- eukaryotic cells
- delivering molecules
- delivering
- interest
- molecule
- Prior art date
Links
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45445089A | 1989-12-21 | 1989-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0506884T3 true DK0506884T3 (da) | 1996-11-04 |
Family
ID=23804657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91903111.2T DK0506884T3 (da) | 1989-12-21 | 1990-12-21 | Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0506884B1 (da) |
| JP (1) | JPH05505102A (da) |
| AT (1) | ATE142266T1 (da) |
| AU (1) | AU658818B2 (da) |
| CA (1) | CA2071214C (da) |
| DE (1) | DE69028412T2 (da) |
| DK (1) | DK0506884T3 (da) |
| ES (1) | ES2091916T3 (da) |
| GR (1) | GR3021474T3 (da) |
| WO (1) | WO1991009958A2 (da) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| NZ239893A (en) * | 1990-09-25 | 1993-11-25 | Hoechst Japan | A method for introducing a foreign dna into a cell |
| US5633230A (en) * | 1990-10-24 | 1997-05-27 | Allelix Biopharmaceuticals, Inc. | Treatment of cytomegalovirus infection |
| WO1993012234A1 (en) * | 1991-12-13 | 1993-06-24 | Sri International | Antiviral reagents based on rna-binding proteins |
| EP0656950B1 (en) * | 1992-08-21 | 1998-11-04 | Biogen, Inc. | Tat-derived transport polypeptides |
| IL106760A (en) * | 1992-08-25 | 1999-12-31 | Miles Inc | Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus |
| ATE302854T1 (de) | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| EP1770168A3 (en) * | 1993-01-26 | 2009-05-06 | The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) | Compositions and methods for delivery of genetic material |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| GB2341390B (en) | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| US5891994A (en) | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
| US7306784B2 (en) | 1998-06-20 | 2007-12-11 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| WO1999067284A2 (en) * | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| JP2003507438A (ja) | 1999-08-24 | 2003-02-25 | セルゲイト， インコーポレイテッド | オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強 |
| US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
| US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US6399067B1 (en) | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| KR100379578B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법 |
| KR100379577B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법 |
| JP2005508832A (ja) | 2001-02-16 | 2005-04-07 | セルゲイト， インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
| JP2003009883A (ja) * | 2001-07-05 | 2003-01-14 | Mitsubishi Pharma Corp | マスト細胞の細胞死誘発剤 |
| KR100495138B1 (ko) * | 2001-07-31 | 2005-06-14 | 학교법인 한림대학교 | 식물세포 투과 도메인-화물분자 복합체 |
| DE10212867B4 (de) * | 2002-03-22 | 2005-07-21 | Hans Prof. Dr. Wolf | Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie |
| KR100472939B1 (ko) * | 2002-05-24 | 2005-03-18 | 학교법인 한림대학교 | 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도 |
| CA2493674A1 (en) | 2002-07-19 | 2004-01-29 | The Regents Of The University Of California | Dendrimers as molecular translocators |
| KR100472937B1 (ko) * | 2002-07-25 | 2005-03-10 | 학교법인 한림대학교 | 세포침투성 티에이티-사이토신 디아미네이즈 융합단백질및 그 용도 |
| US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| US7563437B2 (en) | 2005-02-15 | 2009-07-21 | Thymon, Llc | Methods and compositions for impairing multiplication of HIV-1 |
| WO2006094200A2 (en) * | 2005-03-03 | 2006-09-08 | The Trustees Of Boston College | Method of obtaining a desired localization for cellular imaging with the use of peptidoconjugates |
| US7935816B2 (en) | 2007-10-25 | 2011-05-03 | Gene Tools, Llc | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo |
| EP2618829B1 (en) | 2010-09-22 | 2019-05-01 | The Regents of the University of Colorado, a body corporate | Smad7 for use in the treatment of oral mucositis or psoriasis |
| SG11201507045TA (en) | 2013-03-08 | 2015-10-29 | Univ Colorado Regents | Ptd-smad7 therapeutics |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| EP3790571A4 (en) * | 2018-05-03 | 2022-01-19 | University Of Utah Research Foundation | OCA-B PEPTIDE CONJUGATES AND METHODS OF TREATMENT |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| EP0273085A1 (en) * | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
-
1990
- 1990-12-21 EP EP91903111A patent/EP0506884B1/en not_active Expired - Lifetime
- 1990-12-21 WO PCT/US1990/007607 patent/WO1991009958A2/en active IP Right Grant
- 1990-12-21 AT AT91903111T patent/ATE142266T1/de not_active IP Right Cessation
- 1990-12-21 ES ES91903111T patent/ES2091916T3/es not_active Expired - Lifetime
- 1990-12-21 CA CA002071214A patent/CA2071214C/en not_active Expired - Lifetime
- 1990-12-21 DK DK91903111.2T patent/DK0506884T3/da active
- 1990-12-21 AU AU71829/91A patent/AU658818B2/en not_active Expired
- 1990-12-21 JP JP91503306A patent/JPH05505102A/ja active Pending
- 1990-12-21 DE DE69028412T patent/DE69028412T2/de not_active Expired - Lifetime
-
1996
- 1996-10-24 GR GR960402831T patent/GR3021474T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE142266T1 (de) | 1996-09-15 |
| CA2071214A1 (en) | 1991-06-22 |
| JPH05505102A (ja) | 1993-08-05 |
| DE69028412T2 (de) | 1997-03-27 |
| GR3021474T3 (en) | 1997-01-31 |
| WO1991009958A3 (en) | 1991-08-08 |
| AU658818B2 (en) | 1995-05-04 |
| EP0506884B1 (en) | 1996-09-04 |
| ES2091916T3 (es) | 1996-11-16 |
| CA2071214C (en) | 2006-06-06 |
| EP0506884A1 (en) | 1992-10-07 |
| WO1991009958A2 (en) | 1991-07-11 |
| DE69028412D1 (de) | 1996-10-10 |
| AU7182991A (en) | 1991-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0506884T3 (da) | Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler | |
| AR006188A1 (es) | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". | |
| DK0719340T3 (da) | Klonet glutaminsyre-decarboxylase | |
| AR017866A1 (es) | Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo. | |
| ES2109924T3 (es) | Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas. | |
| AU1049788A (en) | Methods and peptides for the treatment of non-ige-mediated diseases | |
| NO963371L (no) | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det | |
| DK0870022T3 (da) | Immunstimulerende sammensætning og fremgangsmåde | |
| NL300062I1 (nl) | Osteogene middelen. | |
| NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
| ES2151607T3 (es) | Factor 12 de crecimiento y de diferenciacion. | |
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| ES2187648T3 (es) | Metodo para la administracion de farmacos para terapia genica. | |
| PT84089A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
| NO893135L (no) | Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater. | |
| CA2199832A1 (en) | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease | |
| Jones | Protein synthesis in bupivacaine (Marcaine)‐treated, regenerating skeletal muscle | |
| DK1000154T3 (da) | Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering | |
| ATE346919T1 (de) | Nebenhoden-spezifisches rezeptorprotein und dessen verwendung | |
| ES2132027A1 (es) | Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante. | |
| DE69631624D1 (de) | Antikörper gegen menschliches restrictin | |
| EP0372862A3 (en) | Cyclosporine binding protein and its use in an assay for biologically-active cyclosporine | |
| McBride | New molecule under study: Flt3 ligand may mobilize dendritic cells. | |
| WO1990014068A3 (en) | Anti-ergotypic t cells for the treatment or prevention of autoimmune diseases and methods of use thereof | |
| WO1997023607A3 (en) | Presentation of antigen, introduced into cells by stimulation of macropinocytosis |